Logiscreen

Ionis Pharmaceuticals Inc

$74.48
Market Cap 12.30B
ROE -58.6%
Gross Margin 98.8%
Debt/Equity 4.2
Current Ratio 4.1
Revenue QoQ 87.0%
EPS QoQ -0.4%
F-Score 5

About

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.

Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
-37.96
vs median 33.61
P/B
25.26
vs median 2.16
ROE
-0.59
vs median 0.09

Decent quality with acceptable fundamentals

Large-cap company with established market presence

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics